


Aorto-enteric Fistulas Associated with Infected EVARs or Open Prosthetic Grafts: What Are the Differences Between Them and What Are the Implications for Treatment?



Sal Scali, MD
Division of Vascular Surgery & Endovascular Therapy
University of Florida, Gainesville

Wednesday, November 20th, 2024 3:30-3:35PM
Session 45: More Hot Aortic Topics



Disclosures

- None




Open Repair & EVAR

- Both endovascular (EVAR) and open aortic repair (OAR) are susceptible to graft infection.


- *EVAR increasingly supplants OAR*

- Indications for index repair & technical elements of graft removal differ for EVAR & OAR grafts.



Incidence of Aortic Graft Infection

- Aortic graft infection (primary vs. secondary) is rare
~1.6-3% (highest with aorto-femoral bypass)
true incidence unknown/underestimated
- < 1% of aortic operations results in AEF
- 80-90% of AGI are secondary
- If AGI present, aorto-enteric fistula or erosion (AEF/AEE) present in ~25-35% of cases



Lawrence P Semin in Vasc Surg 2011



Controversies in Management





- Several unresolved controversies



Unanswered Questions

- Does infected EVAR differ from an infected in-situ prosthetic graft from a prior open aortic operation?
- Among the subset of AGI with AEF, are there differences in EVAR and Open prosthetic implants?





Demographics & Comorbidities

| Feature, No. (%) | Overall N = 58 | OAR N = 48 | EVAR N = 10 | P-value |
|---------------------------|-------------------|---------------|----------------|---------|
| Age, years (range) | 65 ± 13 | 66 (49-89) | 68 (48-86) | .1 |
| Male sex | 45 (78%) | 38 (79%) | 7 (70%) | .2 |
| BMI | 25 ± 6 | 26 ± 6 | 25 ± 5 | .6 |
| Tobacco exposure | 42 (73%) | 36 (76%) | 6 (60%) | .03 |
| Peripheral artery disease | 25 (43%) | 21 (44%) | 4 (40%) | <.001 |
| End-stage kidney disease | 7 (12%) | 5 (10%) | 2 (20%) | .01 |




No difference in HTN, HLD, CAD or DM

Operative Details


| Feature, No. (%) | Overall N = 58 | OAR N = 48 | EVAR N = 10 | P-value |
|--------------------|-------------------|---------------|----------------|---------|
| ASA class | 3.9 ± 0.5 | 3.9 ± 0.5 | 4.0 ± 0.4 | .6 |
| Multi-stage repair | 7 (13%) | 2 (7%) | 5 (19%) | .4 |
| OR time, Hr:Min | 5:41 ± 2:10 | 5:39 ± 1:47 | 6:03 ± 2:30 | .1 |
| EBL, liters | 3.1 ± 2.9 | 3.2 ± 3.6 | 3.5 ± 1.7 | .06 |
| PRBCs, units | 5.2 ± 3.8 | 4.0 ± 3.2 | 6.4 ± 4.1 | .02 |

- Gram negative organism cultured
OAR: 22% vs EVAR: 53% → p = .001
- Small bowel resection (instead of primary repair)
OAR: 33% vs EVAR: 58% → p = .03

Comparable Overall Outcomes

| | | |
|---|---|---|
| <ul style="list-style-type: none"> Length of stay  <p>20 [14-33] days</p> | <ul style="list-style-type: none"> Complications  <p>Any type 70%</p> | <ul style="list-style-type: none"> Mortality  <p>30-day 35%</p> |
| <ul style="list-style-type: none"> Disposition <p>Home: 29% Rehab: 51% LTAC: 20%</p> | <ul style="list-style-type: none"> Most common <p>Renal injury: 21% Pulmonary: 25% GI: 30%</p> | <ul style="list-style-type: none"> Periop. mortality <p>90-day: 39% 180-day: 42%</p> |

OAR 17% EVAR 34%



Adjusted Mortality Comparisons

Logistic regression OR (95%CI) 30-day death
Cox-regression HR for all-cause mortality

| | |
|-----------------|--|
| GI complication | OR = 1.5, 95%CI 1.0-2, P=.08 HR = 1.2, 95%CI .4-1.6, P=.5 |
| Omental flap | OR = 0.63, 95%CI .2-.8, P=.04 HR = 0.8, 95%CI .4-1.6, P=.6 |
| EVAR | OR = 0.5, 95%CI .09-2.5, P=.4 HR = 0.6, 95%CI .2-1.8, P=.4 |
| GI bleed preop | OR = 2.0, 95%CI .6-6.2, P=.02 HR = 2.0, 95%CI .9-3.9, P=.06 |

- ## Limitations
- Single center, retrospective review
 - Selection bias and modest sample size
 - Patient and anatomic heterogeneity
 - No standardized surgical approach

- ## Conclusions
- EVAR increasingly associated with AGI presentation.
 - Different clinical features for OAR and EVAR AEF.
 - *Variation in symptoms & bacteriology*
 - Operative characteristics comparable but EVAR may present unique technical challenges.
 - *Bare stent, configuration, phlegmon, enteric defect*
 - GI tract repair associated with differences in postop complications and bacteriology are apparent.
 - Overall outcomes are comparable when managed at a high-volume center with experience in treating these complex problems.

Thank You

UF UNIVERSITY of FLORIDA